Zacks Investment Research on MSN

BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?

Beam Therapeutics BEAM and Intellia Therapeutics NTLA are clinical-stage companies developing investigational gene therapies. While BEAM’s pipeline candidates are still in early-stage development, ...

2 stocks that could soar by 52% and 282%, according to Wall Street

This juicy upside potential comes at a cost.
Nasdaq

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

Eli Lilly’s LLY recent announcement to acquire Verve Therapeutics, Inc VERV, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, has put the spotlight on ...
Seeking Alpha

Gene editors steady despite latest leadership shake-up at FDA

Shares of gene editing companies were largely steady in the premarket on Friday after the FDA’s Center for Biologics Research and Evaluation (CBER) faced another abrupt leadership transition following ...
Benzinga.com

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst

On Tuesday, Eli Lilly And Co (NYSE:LLY) agreed to acquire Verve Therapeutics, Inc. (NASDAQ:VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. Lilly ...

Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform

Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine ...
Insider Monkey

Is Regeneron Pharmaceuticals (REGN) One of the Best Gene-Editing Stocks to Buy According to Hedge Funds?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, Canaccord Genuity analyst John Newman reaffirmed a Buy rating on ...

Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress

Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the most oversold biotech stocks to invest in. On November 11, Jones ...

3 European Penny Stocks With Market Caps Under €400M

As European markets navigate a landscape of mixed returns and inflationary pressures, investors are keeping a close eye on potential interest rate adjustments in the U.S. and UK. Amid these broader ...
Business Insider

Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to ...

Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50%

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Powerful New DNA Editing Method Raises Hopes for Cures

Researchers created a highly efficient gene-editing method that fixes multiple DNA mutations in a single step. The breakthrough could revolutionize genetic medicine by making treatments for complex ...